Spectrascience New Stock Fundamentals
Spectrascience New fundamentals help investors to digest information that contributes to Spectrascience New's financial success or failures. It also enables traders to predict the movement of Spectrascience Stock. The fundamental analysis module provides a way to measure Spectrascience New's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spectrascience New stock.
The current year's Research Development is expected to grow to about 937.2 K, whereas Selling General Administrative is forecasted to decline to about 1.4 M. Spectrascience | Select Account or Indicator |
Spectrascience New Company Return On Asset Analysis
Spectrascience New's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Spectrascience New Return On Asset | -0.92 |
Most of Spectrascience New's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spectrascience New is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Spectrascience Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Spectrascience New is extremely important. It helps to project a fair market value of Spectrascience Stock properly, considering its historical fundamentals such as Return On Asset. Since Spectrascience New's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spectrascience New's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spectrascience New's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Spectrascience Total Assets
Total Assets |
|
Based on the latest financial disclosure, Spectrascience New has a Return On Asset of -0.9247. This is 89.43% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Spectrascience New Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spectrascience New competition to find correlations between indicators driving Spectrascience New's intrinsic value. More Info.Spectrascience New is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spectrascience Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spectrascience New's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spectrascience New could also be used in its relative valuation, which is a method of valuing Spectrascience New by comparing valuation metrics of similar companies.Spectrascience New is currently under evaluation in return on asset category among its peers.
Spectrascience Fundamentals
| Return On Asset | -0.92 | ||||
| Current Valuation | 492.38 K | ||||
| Shares Outstanding | 4.92 B | ||||
| Price To Earning | (0.04) X | ||||
| Price To Sales | 73.07 X | ||||
| Revenue | 5.15 K | ||||
| Gross Profit | (194.25 K) | ||||
| EBITDA | (1.99 M) | ||||
| Net Income | (4.47 M) | ||||
| Cash And Equivalents | 27.88 K | ||||
| Total Debt | 6.38 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (1.51 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | -30.43 | ||||
| Market Capitalization | 492.38 K | ||||
| Total Asset | 1.39 M | ||||
| Retained Earnings | (53.97 M) | ||||
| Working Capital | (10.5 M) | ||||
| Current Asset | 479 K | ||||
| Current Liabilities | 10.98 M | ||||
| Net Asset | 1.39 M |
About Spectrascience New Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spectrascience New's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectrascience New using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectrascience New based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 4.6 K | 4.4 K | |
| Cost Of Revenue | 179.5 K | 170.5 K | |
| Stock Based Compensation To Revenue | 1.14 | 1.09 | |
| Sales General And Administrative To Revenue | 217.56 | 228.44 | |
| Research And Ddevelopement To Revenue | 111.25 | 116.82 | |
| Capex To Revenue | 0.45 | 0.42 | |
| Ebit Per Revenue | (545.79) | (518.50) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spectrascience New is a strong investment it is important to analyze Spectrascience New's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectrascience New's future performance. For an informed investment choice regarding Spectrascience Stock, refer to the following important reports:Check out Spectrascience New Piotroski F Score and Spectrascience New Altman Z Score analysis. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (0.92) |
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.